Biotech and Pharma Rebound Expected in 2024 on Innovation Tailwinds
-
Pharma and biotech stocks are poised for gains in 2024 after two down years, fueled by major deals, clinical advances, and new technologies like CRISPR gene editing.
-
The obesity treatment market is booming, led by Eli Lilly and Novo Nordisk; many biotechs aim to differentiate vs their drugs.
-
Gene editing reached a watershed with the first CRISPR drug approval; next-gen editing approaches aim to expand use.
-
Neuroscience could mimic oncology's rise, with new Alzheimer's drugs like Leqembi leading the way.
-
After a wave of mergers, biotechs with high quality assets remain appealing buyout targets for Big Pharma facing patent cliffs.